nach oben

Clinical Pharmacokinetics

Erschienen in:

01.03.2003 | Original Research Article

Investigation of the Mutual Pharmacokinetic Interactions Between Bosentan, a Dual Endothelin Receptor Antagonist, and Simvastatin

verfasst von: Dr Jasper Dingemanse, Dieter Schaarschmidt, Paul L. M. van Giersbergen

Erschienen in: Clinical Pharmacokinetics | Ausgabe 3/2003

Einloggen, um Zugang zu erhalten

Abstract

Background: In vitro, bosentan has been shown to be a mild inducer of cytochrome P450 (CYP) 2C9 and 3A4.

Purpose: To investigate in vivo the mutual pharmacokinetic interactions between bosentan and simvastatin, a CYP3A4 substrate.

Methods: Nine healthy male subjects were treated in a three-period randomised crossover study with: (A) bosentan 125mg twice daily for 5.5 days; (B) simvastatin 40mg once daily for 6 days; and (C) bosentan 125mg twice daily and simvastatin 40mg once daily for 5.5 and 6 days, respectively. Plasma concentration-time profiles of bosentan and its metabolites (treatments A and C) and simvastatin and β-hydroxyacid simvastatin (treatments B and C) were determined on day 6.

Results: Steady-state conditions for bosentan and its metabolites were attained on day 4 of treatment. The pharmacokinetic parameters of bosentan and its metabolites were not influenced by concomitant treatment with simvastatin: areas under the plasma concentration-time curve over one administration interval of 12 hours (AUCτ) [geometric mean and 95% CI] were 4586 (3719–5656) and 4928 (3945–6156) μg · h/L. In contrast, bosentan significantly reduced exposure to simvastatin and β-hydroxyacid simvastatin by 34 and 46%, respectively. AUC> values for simvastatin were 30.5 (23.1–40.2) and 20.0 (15.9–25.1) μg · h/L and for β-hydroxyacid simvastatin 43.0 (32.1–57.8) and 23.4 (16.7–32.6) μg · h/L in treatments B and C, respectively.

Conclusion: Concomitant treatment with bosentan reduces the exposure to simvastatin and β-hydroxyacid simvastatin by approximately 40%, indicating that in vivo bosentan is also a mild inducer of CYP3A4.

Use of tradenames is for product identification only and does not imply endorsement.

Yanagisawa M, Kurihara H, Kimura S, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988; 332: 411–5PubMedCrossRef

Ray A, Hegde LG, Chugh A, et al. Endothelin-receptor antagonists: current and future perspectives. Drug Discov Today 2000; 5: 455–64PubMedCrossRef

Wu C. Recent discovery and development of endothelin receptor antagonists. Exp Opin Ther Patents 2000; 10: 1653–68CrossRef

Giannessi D, Del Ry S, Vitale RL. The role of endothelins and their receptors in heart failure. Pharmacol Res 2001; 43: 11–126CrossRef

Lüscher TF, Barton M. Endothelins and endothelin receptor antagonists: therapeutic considerations for a novel class of cardiovascular drugs. Circulation 2000; 102: 2434–40PubMedCrossRef

Chakrabarti S, Cukiernik M, Mukherjee S, et al. Therapeutic potential of endothelin receptor antagonists in diabetes. Expert Opin Investig Drugs 2000; 9: 2873–88PubMedCrossRef

Clozel M, Breu V, Gray GA, et al. Pharmacological characterization of bosentan, a new potent orally active nonpeptide endothelin receptor antagonist. J Pharmacol Exp Ther 1994; 270: 228–35PubMed

Weber C, Schmitt R, Birnboeck H, et al. Pharmacokinetics and pharmacodynamics of the endothelin-receptor antagonist bosentan in healthy human subjects. Clin Pharmacol Ther 1996; 60: 124–37PubMedCrossRef

Roux S, Breu V, Ertel SI, et al. Endothelin antagonism with bosentan: a review of potential applications. J Mol Med 1999; 77: 364–76PubMedCrossRef

10.

Channick RN, Simonneau G, Sitbon O, et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet 2001; 358: 1119–23PubMedCrossRef

11.

Kiowski W, Suetsch G, Hunziker P, et al. Evidence of endothelin-1 mediated vasoconstriction in severe chronic heart failure. Lancet 1995; 346: 732–6PubMedCrossRef

12.

Suetsch G, Kiowski W, Yan X-W, et al. Short-term endothelin receptor antagonist therapy in conventionally treated patients with symptomatic severe chronic heart failure. Circulation 1998; 98: 2262–8CrossRef

13.

Weber C, Schmitt R, Birnboeck H, et al. Multiple-dose pharmacokinetics, safety, and tolerability of bosentan, an endothelin receptor antagonist, in healthy male volunteers. J Clin Pharmacol 1999; 39: 703–14PubMedCrossRef

14.

Weber C, Gasser R, Hopfgartner G. Absorption, excretion, and metabolism of the endothelin receptor antagonist bosentan in healthy male subjects. Drug Metab Dispos 1999; 27: 810–5PubMed

15.

Smith DA. Induction and drug development. Eur J Pharm Sci 2000; 11: 185–9PubMedCrossRef

16.

Weber C, Banken L, Birnboeck H, et al. Effect of the endothelin-receptor antagonist bosentan on the pharmacokinetics and pharmacodynamics of warfarin. J Clin Pharmacol 1999; 39: 847–54PubMedCrossRef

17.

Lennernäs H, Fager G. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors: similarities and differences. Clin Pharmacokinet 1997; 32: 403–25PubMedCrossRef

18.

Prueksaritanont T, Gorham LM, Bennett MA, et al. In vitro metabolism of simvastatin in humans: identification of metabolizing enzymes and effect of the drug on hepatic P450s. Drug Metab Dispos 1997; 25: 1191–9PubMed

19.

Mauro VF. Clinical pharmacokinetics and practical applications of simvastatin. Clin Pharmacokinet 1993; 24: 195–202PubMedCrossRef

20.

Tucker GT, Houston JB, Huang S-M. Optimising drug development: strategies to assess drug metabolism/transporter interaction potential: towards a consensus. Clin Pharmacol Ther 2001; 70: 103–14PubMedCrossRef

21.

Lausecker B, Hess B, Fischer G, et al. Simultaneous determination of bosentan and its three major metabolites in various biological matrices and species using narrow bore liquid chro matography with ion spray tandem mass spectrometric detection. J Chromatogr B Biomed Sci Appl 2000; 749: 67–83PubMedCrossRef

22.

Gibaldi M, Perrier D. Pharmacokinetics. 2nd ed. New York: Marcel Dekker Inc, 1982

23.

Pichard L, Fabre I, Daujat M, et al. Effect of corticosteroids on the expression of cytochromes P450 and on cyclosporin A oxidase activity in primary cultures of human hepatocytes. Mol Pharmacol 1992; 41: 1047–55PubMed

24.

Van Giersbergen PLM, Treiber A, Clozel M, et al. In vitro and in vivo studies exploring the pharmacokinetic interaction between bosentan, a dual endothelin receptor antagonist, and glyburide. Clin Pharmacol Ther 2002; 71: 253–62PubMedCrossRef

25.

Dingemanse J, Bodin F, Weidekamm E, et al. Influence of food intake and formulation on the pharmacokinetics and metabolism of bosentan, a dual endothelin receptor antagonist. J Clin Pharmacol 2002; 42: 283–9PubMedCrossRef

26.

Prueksaritanont T, Vega JM, Rogers JD, et al. Simvastatin does not affect CYP3A activity, quantified by the erythromycin breath test and oral midazolam pharmacokinetics, in healthy male subjects. J Clin Pharmacol 2000; 40: 1274–9PubMed

27.

Bogman K, Peyer AK, Torok M, et al. HMG-CoA reductase inhibitors and P-glycoprotein modulation. Br J Pharmacol 2001; 132: 1183–92PubMedCrossRef

28.

Wang E, Casciano CN, Clement RP, et al. HMG-CoA reductase inhibitors (statins) characterized as direct inhibitors of P-glycoprotein. Pharm Res 2001; 18: 800–6PubMedCrossRef

29.

Weber C, Banken L, Birnboeck H, et al. The effect of bosentan on the pharmacokinetics of digoxin in healthy male subjects. Br J Clin Pharmacol 1999; 47: 701–6PubMedCrossRef

30.

Desager JP, Horsmans Y. Clinical pharmacokinetics of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors. Clin Pharmacokinet 1996; 31: 348–71PubMedCrossRef

31.

Corsini A, Bellosta S, Baetta R, et al. New insights into the pharmacodynamic and pharmacokinetic properties of statins. Pharmacol Ther 1999; 84: 413–28PubMedCrossRef

32.

Kyrklund C, Backman JT, Kivistö KT, et al. Rifampin greatly reduces plasma simvastatin and simvastatin acid concentrations. Clin Pharmacol Ther 2000; 68: 592–7PubMedCrossRef

33.

Heimark LD, Gibaldi M, Trager WF, et al. The mechanism of the warfarin-rifampin drug interaction in humans. Clin Pharmacol Ther 1987; 42: 388–94PubMedCrossRef

34.

Fuhr U. Induction of drug metabolising enzymes: pharmacokinetic and toxicological consequences in humans. Clin Pharmacokinet 2000; 38: 493–504PubMedCrossRef

35.

Quattrochi LC, Guzelian PS. CYP3A regulation: from pharmacology to nuclear receptors. Drug Metab Dispos 2001; 29: 615–22PubMed

Titel: Investigation of the Mutual Pharmacokinetic Interactions Between Bosentan, a Dual Endothelin Receptor Antagonist, and Simvastatin
verfasst von: Dr Jasper Dingemanse
Dieter Schaarschmidt
Paul L. M. van Giersbergen
Publikationsdatum: 01.03.2003
Verlag: Springer International Publishing
Erschienen in: Clinical Pharmacokinetics / Ausgabe 3/2003
Print ISSN: 0312-5963
Elektronische ISSN: 1179-1926
DOI: https://doi.org/10.2165/00003088-200342030-00004

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten